Platelet Activation and Clopidogrel Effects on ADP-Induced Platelet Activation in Cats with or without the A31P Mutation in MYBPC3

R.H.L. Li, J.A. Stern, V. Ho, F. Tablin†, and S.P. Harris†

Background: Clopidogrel is commonly prescribed to cats with perceived increased risk of thromboembolic events, but little information exists regarding its antiplatelet effects. Objective: To determine effects of clopidogrel on platelet responsiveness in cats with or without the A31P mutation in the MYBPC3 gene. A secondary aim was to characterize variability in feline platelet responses to clopidogrel. Animals: Fourteen healthy cats from a Maine Coon/outbred mixed Domestic cat colony: 8 cats homozygous for A31P mutation in the MYBPC3 gene and 6 wild-type cats without the A31P mutation. Methods: Ex vivo study. All cats received clopidogrel (18.75 mg PO q24h) for 14 days. Before and after clopidogrel treatment, adenosine diphosphate (ADP)-induced P-selectin expression was evaluated. ADP- and thrombin-induced platelet aggregation was measured by optical aggregometry (OA). Platelet pVASP and ADP receptor response index (ARRI) were measured by Western blot analysis.

Results: Platelet activation from cats with the A31P mutation was significantly (P = .0095) increased [35.55% (18.58–48.55) to 58.90% (24.85–69.90)], in response to ADP. Clopidogrel treatment attenuated ADP-induced P-selectin expression and platelet aggregation. ADP- and PGE1-treated platelets had a similar level of pVASP as PGE1-treated platelets after clopidogrel treatment. Clopidogrel administration resulted in significantly lower ARRI [24.13% (12.46–35.50) to 11.30% (7.383–23.27)] (P = .017). Two of 13 cats were nonresponders based on OA and flow cytometry.

Conclusion and Clinical Importance: Clopidogrel is effective at attenuating platelet activation and aggregation in some cats. Cats with A31P mutation had increased platelet activation relative to the variable response seen in wild-type cats.

Key words: Cat; Hypertrophic cardiomyopathy; Platelet hyper-reactivity; Thromboembolism.

A T E is a life-threatening complication associated with HCM in cats. Thrombi in left atrial appendages (LAA) of cats can embolize to peripheral and central arteries causing tissue ischemia, ischemic reperfusion injury, and sudden death.1–3 Despite recent advances in thrombosis research, the underlying role of platelets in the pathophysiology of ATE in cats remains poorly understood.

In people, platelet activation and increased P-selectin expression are associated with myocardial inflammation, myocardial infarction, and cardiomyopathy.5–6 Platelet reactivity predicts thromboembolic events associated with myocardial infarct and coronary stent implantation.7–9 Altered platelet function occurs in cats with HCM.10,11 Main Coon cats with severe HCM because of a mutation (A31P) in the myosin-binding protein C (MYBPC3) gene have increased expression of P-selectin, platelet-derived microvesicles (PMVs), and platelet–endothelial cell adhesion molecule-1.11 This suggested that platelets might play a prominent role in the development of the hypercoagulable state in feline HCM.

Clopidogrel, an antiplatelet drug, effectively inhibits ADP-induced platelet aggregation in healthy cats.12,13 Here, we sought to determine whether clopidogrel would be a logical treatment option in cats with perceived risk of ATE.3,14 In human patients, clopidogrel is a key component of antithrombotic treatment in patients with acute ischemic stroke and coronary stent implantation.15–17 However, substantial interindividual variability exists and resistance to clopidogrel is

**Abbreviations:**

ADP
adenosine diphosphate

ADP-Ag
ADP-induced platelet aggregation

ARRI
ADP receptor response index
cAMP
cyclic adenosine monophosphate

HO
homozygous for the A31P mutation

MA
maximum amplitude

MYBPC3
myosin-binding protein C gene

OA
optical aggregometry

pVASP
phosphorylated vasodilator-stimulated phosphoprotein

PGE1
prostaglandin E1

PMV
platelet-derived microvesicles

PRP
platelet-rich plasma

Throm-Ag
thrombin-induced platelet aggregation

VASP
vasodilator-stimulated phosphoprotein

WT
wild type with respect to the A31P mutation

**From the Department of Anatomy, Physiology and Cell Biology, School of Veterinary Medicine, University of California Davis, Davis, CA (Li, Ho, Tablin); the Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California Davis, Davis, CA (Stern); and the Department of Cellular and Molecular Medicine, College of Medicine, University of Arizona, Tucson, AZ (Harris) All work was performed at the University of California, Davis.**

The study was presented at the International Veterinary Emergency and Critical Care Symposium, Washington, DC, September 2015. These two individuals contributed equally as senior authors.

†Tablin and Harris are senior authors.

Corresponding author: Dr R.H.L. Li, Department of Anatomy, Physiology and Cell Biology, School of Veterinary Medicine, University of California, Davis, One Shields Ave, Davis, CA 95616; e-mail: rhl@ucdavis.edu

Submitted October 28, 2015; Revised May 23, 2016; Accepted August 2, 2016.

Copyright © 2016 The Authors, Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

DOI: 10.1111/jvim.14568
associated with recurrent thrombosis and increased morbidity. Although clopidogrel is commonly prescribed to cats with ATE, little is known regarding its effects on platelet activation and response variability.

The primary aim of this study was to evaluate the response of feline platelets to clopidogrel and to characterize variability in response to clopidogrel. The secondary aim of this study was to characterize platelet activation and aggregation in cats homozygous for the MYBPC3 A31P mutation before development of the recognized phenotype of HCM. We hypothesized that cats homozygous (HO) for the MYBPC3 A31P mutation would have hyper-reactive platelets compared to wild-type (WT) cats without the A31P mutation. We also hypothesized that clopidogrel would attenuate platelet sensitivity to ADP and that cats would exhibit a highly variable response to clopidogrel treatment.

Materials and Method

Animals

The study protocol was approved by the Institutional Animal Care and Use Committee at the University of California, Davis. Fourteen cats were selected from a newly established colony of Maine Coon/outbred mixed domestic cats. Eight cats homozygous (HO) for A31P mutation in the MYBPC3 gene and 6 wild-type (WT) cats without the A31P mutation were studied. Cats were between 12 and 44 months (median 18.5 months) of age. As part of a separate and ongoing longitudinal study, cardiac echocardiography was assessed for all 14 cats within 2 months before the start of this study. None of the cats had echocardiographic evidence of HCM at the time of the study, and all were considered clinically healthy. Cats were observed for adverse reactions to clopidogrel such as vomiting, inappetence, diarrhea, weight loss, and bleeding diathesis. On rare occasions, blood samples from cats were not included in portions of the study, as sample clotting and inadequate volume of platelet-rich plasma (PRP) prevented evaluation. If either blood samples taken before or after clopidogrel were clotted, data from that animal were not included in this portion of the study.

Each cat received 18.75 mg clopidogrel PO for 14 days. Blood was collected on day 0 (1 day before clopidogrel administration) and day 15 (approximately 12 hours after the last clopidogrel dose was administered). Complete blood counts were obtained using an automated analyzer. All cats were sedated with a combination of acepromazine (0.05 mg/kg IM) and butorphanol (0.2 mg/kg IM) before venipuncture. Additional doses of acepromazine, butorphanol, or both were administered if required. Blood was drawn from the medial saphenous vein using a 21-gauge butterfly needle set, and 8 ml of blood was collected into 3.2% trisodium citrate tubes.

Response to clopidogrel was characterized based on the percentage of change of ADP-induced platelet aggregation (ADP-Ag) before and after the 14-day clopidogrel treatment. Subjects with ≤10% inhibition of ADP-Ag after clopidogrel treatment were classified as nonresponders. Cats with >10% inhibition of ADP-Ag after clopidogrel treatment were considered responders.

Generation of Platelet-Rich Plasma

Citrated whole blood was transferred to polypropylene tubes and diluted (1:5) with Tyrodes–HEPES buffer lacking divalent cations but containing 5 mM dextrose (37°C). PRP was generated by centrifugation at 200 x g for 5 minutes at 25–27°C.

Flow Cytometry

PRP platelet count was adjusted to 1 x 10^7/mL with Tyrodes–HEPES buffer. Platelets were either unstimulated (resting) or stimulated (activated) with 20 μM ADP and incubated for 15 minutes (37°C) before the addition of antibodies. Samples were incubated with monoclonal antibodies to CD62P and biotinylated monoclonal antibodies to CD41b at a final dilution of 1:100, respectively, for 45 minutes at 37°C. Samples were then labeled with streptavidin conjugated to Alexa 633 (30 minutes) and fixed in 1% paraformaldehyde in Tyrodes–HEPES buffer.

Flow cytometry was performed using a 5-color flow cytometer. Anti-mouse compensation beads and monoclonal mouse immunoglobulin G1 kappa conjugated to matched experimental fluorochromes were used for compensation controls. Platelets were identified by forward and side scatter properties and by 0.9 μm and 3 μm compensation controls. For the identification of CD62P (P-selectin) and CD41b (α2b subunit of the major platelet integrin, α2bβ3)-positive events within the platelet gate, gating boundaries were identified by the use of fluorescence-minus-one controls.

Platelet-derived microvesicles (PMVs) were identified as previously described by Robert et al. Briefly, the microvesicle gate was determined by the use of 0.5 μm and 3 μm calibration beads. The identification of CD62P (P-selectin) and CD41b (α2bβ3 subunit of the major platelet integrin, α2bβ3)-positive events within the platelet gate, gating boundaries were identified by the use of fluorescence-minus-one controls.

PMVs were quantified by dividing the number of CD41b-positive events by the total number of events within the microvesicle gate and expressed as percentages. Flow cytometry data were analyzed by commercially available software.

Western Blot Analyses of Intracellular Phosphorylation of Vasodilator-Stimulated Phosphoprotein (VASP)

Phosphorylation of the intracellular protein, VASP, was quantified by Western blot analysis using affinity-purified polyclonal antibodies. PRP from homozygous and wild-type cats was generated as described above and diluted with Tyrodes–HEPES buffer to a final platelet concentration of 1 x 10^7/mL. Samples were incubated with ADP (20 μM), prostaglandin E1 (PGE1) (10 μM), or a combination of ADP (20 μM) and PGE1 (10 μM), all incubations for 10 minutes, 37°C. Unstimulated samples served as the resting control population.
whereas PGE$_1$-induced VASP phosphorylation served as the positive control population. Samples were then lysed in Laemmli buffer$^2$ with antiproteases and antiphosphatases (leupeptin, pepstatin, trypsin inhibitor soybean, AEBSF, sodium orthovanadate, EDTA$^3$ (aprotinin and sodium fluoride)$^4$) and stored at −80°C until further analysis.

Samples were evaluated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. Membranes were blocked with 3% gelatin at 37°C. Affinity-purified antibodies were used to detect phosphorylation of serine 239 (pVASP)$^5$ and total VASP.$^6$ These antibodies were chosen based upon high sequence homology when evaluated against the published feline VASP protein (XP_006941169). Amino acid sequences of pVASP and VASP antibodies were highly homologous (100% positive with 0 gaps, respectively) when compared to the published feline VASP protein sequence as determined by the Basic Local Alignment Search Tool, BLAST.$^7$ The reaction runs for 5 additional minutes.

Immunoblotting and imaging for pVASP were performed first followed by stripping of primary and secondary antibodies using commercially available stripping buffer. To confirm specificity of antibody binding after stripping, blots were incubated with secondary antibodies against host animal (goat) in which the primary antibody was generated. Blots that showed no residual antibody, as judged by the lack of secondary antibody labeling in the absence of primary antibody, were probed for total VASP on the same membrane. Antibody labeling in the absence of primary antibody, as judged by the lack of secondary antibody labeling in the absence of primary antibody, were probed for total VASP on the same membrane.

Thrombin-induced aggregation (Throm-Ag) served as positive control. Percentage of maximal aggregation (amplitude) was calculated using commercially available software.$^8$

**Response to Clopidogrel**

The response of each cat to clopidogrel treatment was categorized based on previously established criteria for human patients.$^9$ Percent inhibition was calculated by the following formula:

\[
\text{Percent Inhibition} = \left( \frac{\text{OD}_{\text{ADP-AgPRETREATMENT}} - \text{OD}_{\text{ADP-AgPOST-TREATMENT}}}{\text{OD}_{\text{ADP-AgPRETREATMENT}}} \right) \times 100
\]

**Statistical Analysis**

Normality was tested using the Shapiro–Wilk normality test. Normally distributed and paired data were analyzed using $t$-test. Nonparametric and paired data were analyzed using the Wilcoxon signed-rank test. Pearson correlation coefficients were calculated to describe the agreement between different platelet function assessments. Interindividual variability was calculated as the ratio between the standard deviation of a group and its mean (coefficient of variation). Parametric data were presented as mean ± standard deviation, and nonparametric data were presented as median and interquartile range (IQR). Statistical analysis was performed using commercially available software.$^9$ An a priori alpha of $P < .05$ was considered statistically significant.

**Results**

**Flow Cytometry**

Before clopidogrel treatment, ADP stimulation resulted in a significantly higher percentage of P-selectin-positive platelets and P-selectin mean fluorescence intensity (MFI) as compared to unstimulated (resting) platelets (Fig 1). Mean percentages of P-selectin-positive platelets were 35.53 ± 21.42% in resting platelets and 46.75 ± 6.27% in ADP-activated platelets. ADP stimulation resulted in a significant increase in P-selectin MFI (from 4791 ± 2598 to 7412 ± 4702) ($P = .0067$). However, after 14 days of clopidogrel treatment, no significant differences in percentage of P-selectin-positive platelets and P-selectin MFI were identified between ADP-stimulated activation and resting platelets ($P = .87$, $P = .52$, respectively) (Fig 2). Mean percentages of P-selectin-positive platelets were 50.49 ± 21.85% in resting platelets and 51.55 ± 20.39% in ADP-activated platelets. Mean P-selectin MFIs were 453 ± 1272 (resting) and 4350 ± 1519 (activated).

In cats, HO for A31P mutation of the MYPBC3 gene, ADP-induced P-selectin expression (P-selectin MFI and percentage of P-selectin-positive platelets) was significantly higher as compared to resting platelets ($P = .0095$, $P = .016$). Before clopidogrel treatment, all cats HO for A31P mutation, but one, had an increase in P-selectin-positive platelets after ADP.

1621
stimulation. Median percentages of P-selectin-positive platelets in resting and activated platelets were 35.55% (IQR: 18.58–48.55) and 58.90% (IQR: 24.85–69.90), as shown next to the data points (Fig 3A). Not all HO cats had elevated P-selectin MFI after ADP stimulation but 4 of 8 cats had substantial increase. When compared to resting platelets, ADP activation resulted in a significant increase in median platelet MFI [from 3215 (IQR: 2347–5904) to 5758 (IQR: 2590–12197)] in HO cats (P = .035) (Fig 3B). The response to ADP was variable in WT cats, with platelets from 2 of 6 cats showing minimal to no response to ADP (Fig 3C and D). Median percentages of P-selectin-positive platelets were 34.30% (IQR: 14.27–64.35) and 44.70% (IQR: 15.20–71.08) in resting and activated platelets, respectively. No significant increase in P-selectin-positive platelets (B) and P-selectin MFI (C) as compared to resting platelets. The bolded line represents the mean and the upper and lower lines represent the standard deviations.

Fig 1. Flow cytometric analysis of P-selectin expression in 14 cats before clopidogrel treatment. (A) Representative histogram of resting platelets (blue) and ADP-activated platelets (red) indicating the significant increase in platelet P-selectin expression before clopidogrel treatment. ADP-induced stimulation resulted in significant increase of percentage (%) in P-selectin-positive platelets (B) and P-selectin MFI (C) as compared to resting platelets. The bolded line represents the mean and the lower and upper lines represent the standard deviations.

Fig 2. Flow cytometric analysis of P-selectin expression in 14 cats after clopidogrel treatment (day 15). (A) Representative histogram of resting platelets (blue) and ADP-activated platelets (red) after clopidogrel treatment. After 14 days of clopidogrel treatment, no significant changes in P-selectin expression were seen in resting (blue) and ADP-activated platelets (red). ADP-induced stimulation did not result in a significant increase of percentage (%) of P-selectin-positive platelets (B) and P-selectin MFI (C) as compared to resting platelets. The bolded line represents the mean and the upper and lower lines represent the standard deviations.
was found after ADP-induced activation ($P = .16$).

After 14 days of clopidogrel treatment, no significant differences in P-selectin-positive platelets and P-selectin MFI were found in resting and activated platelets in either HO or WT cats (Fig 4). ADP stimulation did not result in significant increase in percentage (%) of P-selectin platelets in either HO ($P = .84$) or WT ($P = .44$) cats compared to resting platelets (Fig 4A). In HO cats, median P-selectin-positive platelets were 47.10% (IQR: 37.83–65.28) and 43.35% (IQR: 39.60–64.08) in resting and activated platelets, respectively. In WT cats, median P-selectin-positive platelets were 58.10% (IQR: 30.18–71.80) (resting) platelets and 52.40% (IQR: 32.42–64.06) (activated). ADP stimulation did not result in significant increase in P-selectin MFI compared to resting platelets in either HO ($P = .73$) or WT ($P = .44$) cats. In HO cats, median P-selectin MFI was 4353 (IQR: 3061–5039) (resting) and 4026 (IQR: 2976–5449) (activated). In WT cats, median P-selectin MFI was 4633 (IQR: 3820–5805) (resting) and 4600 (IQR: 3915–5480) (activated).

Before clopidogrel treatment, mean PMVs were 25.12 ± 16.07% (resting) and 20.42 ± 17.46% (activated) in all cats. After clopidogrel treatment, mean PMVs were 15.34 ± 18.12% (resting) and 17.42 ± 21.40% (activated). ADP stimulation did not result in significant differences in the number of PMVs compared to resting platelets ($P = .39$), nor were there any differences compared to postclopidogrel resting samples ($P = .54$).

When examining PMVs based on genotype, ADP stimulation resulted in an increase in PMVs [5.67% (IQR: 1.47–36.90) to 10.67% (IQR: 2.28–44.75)] before clopidogrel treatment in cats HO for A31P mutation, but the difference was not statistically significant ($P = .25$). In WT cats, PMVs did not significantly increase after stimulation with ADP [resting: 6.45% (IQR: 3.37–19.48), activated: 3.43% (IQR: 2.25–22.80)] before treatment ($P = .44$). After clopidogrel treatment, no significant differences in PMVs were noted between resting (27.45%, IQR: 8.14–47.65) and activated (23.70%, IQR: 11.19–32.45) in HO cats. Similarly, no differences in PMVs were found in WT cats (resting: 23.75% (IQR: 15.47–29.43), activated: 13.35% (IQR: 4.96–20.48)) ($P = .43$).

### Optical Aggreometry

The amplitude of ADP-Ag was not significantly different from Throm-Ag on day 0 ($P = .93$). The mean maximum amplitudes (MA) of ADP-Ag and Throm-Ag were 51 ± 24.25% and 61.92 ± 19.48%, respectively. However, after 14 days of clopidogrel treatment, the mean MA of ADP-Ag (8.54 ± 4.72%) was significantly lower than Throm-Ag (56.25 ± 28.33%) in all cats ($P = .001$). ADP-Ag was significantly higher on day 0 than on day 15 ($P = .0002$). Throm-Ag on days 0 and 15 was not significantly different ($P = .68$) (Fig 5).

Before clopidogrel treatment, ADP-Ag [median MA: 47.50% (IQR: 21.25–73)] was not significantly different from Throm-Ag [median MA: 63% (IQR: 34.00–76)] in HO cats ($P = .45$). Similarly in WT cats, ADP-Ag [median MA: 68% (IQR: 41–71)] was not different from Throm-Ag [median MA: 71% (IQR: 60–82)] in WT cats ($P = .31$). On day 15, significant reduction in ADP-Ag [median MA: 9.50% (IQR: 6.25–10.75)] was found in HO cats when compared to Throm-Ag [median MA: 47.50% (IQR: 34.00–76)] in HO cats ($P = .016$). In WT cats, ADP-Ag [median MA: 9.00% (3.00–14.50)] was significantly lower than Throm-Ag [median MA: 65% (IQR: 37.00–79.50)] ($P = .040$). As

![Fig 3](image-url)
expected, clopidogrel treatment did not lead to a significant decrease in the MA of Throm-Ag in either HO or WT cats ($P = .750$, $P = .438$, respectively). ADP-Ag amplitude in HO cats was not significantly different from ADP-Ag in WT cats on day 15 ($P = .65$). Because of inadequate volume of PRP on day 0 and sample clotting on day 15 in a single cat (WT), no optical aggregometry data were available from that subject.

**Platelet VASP Phosphorylation and ADP Receptor Response Index**

Two cats (1 WT and 1 HO) were excluded from Western blot analyses because of inadequate PRP volume on day 0.

Representative Western blots are shown in Figure 6. Before clopidogrel treatment, the mean relative pVASP intensities of PGE$_1$-treated platelets (0.54 ± 0.24) were not significantly different from either resting (0.58 ± 0.32) or ADP-treated (0.46 ± 0.21) platelets ($P = .44$, $P = .21$, respectively). However, before clopidogrel treatment, relative pVASP was significantly lower in PGE$_1$+ADP-treated platelets (0.43 ± 0.20) than in platelets treated with PGE$_1$ alone ($P = .049$) (Fig 7A).

After 14 days of clopidogrel treatment, relative pVASP in platelets treated with PGE$_1$ and ADP was not significantly different from platelets treated with PGE$_1$ alone ($P = .62$) (Fig 7A). Mean relative pVASP was not significantly different among PGE$_1$-treated (0.55 ± 0.22), resting (0.37 ± 0.25), and ADP-treated (0.37 ± 0.18) platelets ($P = .21$, $P = .21$, respectively). ARRI after clopidogrel treatment was significantly lower than ARRI before treatment ($P = .017$) (Fig 7B). The median ARRI was 24.13% (IQR: 12.46–35.50).
and 11.30% (IQR: −7.383 to 23.27) on day 0 and day 15, respectively.

Response to Clopidogrel

None of the cats displayed clinical signs suggestive of adverse reactions to clopidogrel. Of 13 samples available for optical aggregometry, 2 nonresponders and 11 responders to clopidogrel treatment were identified based on platelet response to ADP-Ag. Both nonresponders had low ADP-Ag before and after clopidogrel treatment (1–3% and 18–20%). The median percent inhibition among responders was 86.21% (IQR: 81.82–88.71). ADP stimulation also did not result in a significant increase in percent-positive P-selectin when compared to resting platelets of responders. The two nonresponders showed variable increases in P-selectin MFI despite clopidogrel treatment whereas virtually all responders, with one exception, had decreased P-selectin expression (Fig 8). ARRI was also significantly decreased in responders after treatment (P = .020). Nonresponders also were observed to have reduced ARRI after clopidogrel treatment. Within the population of responders, 7 cats were HO and 4 cats were WT.

Overall, interindividual variability in response to clopidogrel treatment was high, ranging from 34.92 to 100% depending on the tests used to assess clopidogrel response. Measurement of ARRI using Western blot analysis had the highest interindividual variability (CVARRI = 26.9) whereas flow cytometric detection of P-selectin expression had the lowest interindividual variability (CVMFI = 0.55, CV% = 0.40). ADP-Ag using OA had a CV of 0.55.

Discussion

In the absence of HCM, cats HO for the A31P mutation of the MYPBC3 gene had reactive platelets as measured by increased ADP-induced P-selectin expression relative to the more variable response seen in WT cats. Here, we showed that 14 days of clopidogrel treatment attenuated ADP-mediated P-selectin expression on platelets from either HO or WT cats, illustrating the potent antiplatelet effects of clopidogrel in apparently healthy cats with or without the A31P mutation. A dosage of 18.75 mg, PO, given every 24 hours for 14 days also resulted in significant inhibition of ADP-induced aggregation and increase in pVASP. Once metabolized in the liver, the active metabolite of clopidogrel covalently binds with P2Y12, one of two platelet ADP receptors. P2Y12 is a purinergic class of G-protein-coupled receptor and clopidogrel abolishes ADP-mediated downstream signaling by inhibiting inside-out activation of the platelet integrin, a2b3, which is critical for platelet aggregation.24,25 The profound inhibition of platelet aggregation after clopidogrel treatment observed in this study indicates that a
similar mechanism of action likely occurs in feline platelets.

P-selectin, an integral protein of the α-granule membrane, is exposed on the platelet surface by fusion of the α-granule membrane with plasma membrane. Because fusion is necessary for platelet granule secretion, surface expression of P-selectin serves as a useful marker of ADP-induced platelet activation and granule secretion. Upon ADP stimulation, platelet P-selectin expression in cats HO for the A31P mutation was significantly upregulated. This finding further suggests the conclusion that cats with genetic predisposition to HCM have procoagulant platelets that predispose them to intracardiac thrombi formation and increased risk for ATE. Platelet P-selectin expression in this population of cats was generally higher than previously reported. The differences in results were likely because of the use of different CD62P antibodies, in vitro activation from sample handing and centrifugation, age and genetic differences between the studied populations. In humans, platelet reactivity is associated with mortality and morbidity from cardiovascular events and death. Platelet reactivity can be the result of platelet priming, a regulatory mechanism that amplifies the platelet response to agonists and, thus, contributes to thrombus formation and growth. For that reason, neutralization of platelet priming presents a novel treatment paradigm for thrombus prevention, and thus, further studies in HCM cats are warranted.

The attenuated ADP-induced P-selectin expression by clopidogrel treatment suggests additional benefits of this drug in ATE cats. Because the binding of P-selectin to its ligand, P-selectin glycoprotein ligand–1, facilitates recruitment of leukocytes to thrombi and enhances platelet–leukocyte interactions, attenuation of expression by capturing leukocyte-derived microvesicles, inhibition of this interaction may further reduce the progression of thrombosis and inflammation. Spon
taneous echocardiographic contrast, a swirling blood flow pattern associated with blood stasis in the LAA, is a common finding and a suggested predictor of boembolic outcomes in feline HCM. A study utilizing direct analysis of left atrial blood showed that human patients with spontaneous echocardiographic contrast had increased platelet P-selectin expression and platelet–leukocyte aggregates. However, it remains unknown whether elevated P-selectin expression in cats predisposed to HCM could be associated with increased platelet–neutrophil interaction and spontaneous echocardiographic contrast in the LAA. Considering that several ex vivo studies have demonstrated the effectiveness of clopidogrel in attenuating platelet–leukocyte adhesion and platelet-dependent leukocyte activation, further studies are required to investigate the effects of clopidogrel on platelet–leukocyte interactions in cats.

Clopidogrel did not affect ADP-mediated expression of PMVs in the present study. Studies on human platelets have shown that P2Y12 receptors are involved in PMV formation, loss of phospholipid asymmetry and externalization of phosphatidylinerine. There are several reasons that may explain the negative results found in this study. Firstly, although P2Y12 potentiates PMV formation, ADP, when used alone, is considered a weak agonist and may lack the ability to induce PMV formation in vitro. Furthermore, the use of citrate as an anticoagulant might have inhibited PMV formation because low extracellular calcium concentration prevents activation of calcium-dependent calpain, which facilitates PMV formation by degrading structural proteins such as actin-binding proteins. Therefore, cats with severe HCM were demonstrated to have a significant increase in PMV, it is also possible that PMV formation could be associated with disease severity and that the lack of clinical HCM precluded any significant changes in PMV formation.

In human platelets, the binding of ADP to P2Y12 activates the G-protein, Gαi2, which inhibits adeny
cyclase and reduces cyclic AMP (cAMP). cAMP, an important mediator of platelet reactivity, stimulates cAMP-dependent protein kinase A, which phosphorylates a number of substrate proteins responsible for platelet activation. Therefore, increases in cAMP, therefore, decreases the activation of protein kinase A resulting in decreased phosphorylation of VASP. The active metabolite of clopidogrel irreversibly binds to P2Y12 and abolishes the downstream signaling causing increases in cAMP and pVASP. Because PGE1 increases intracellular cAMP and causes subsequent VASP phosphorylation, PGE1-stimulated platelets served as controls in this study.

The present study showed an important degree of interindividual variability in response to a defined dose of clopidogrel suggesting that some cats may not be adequately protected from ATE. This heterogeneous response to clopidogrel is well described in human beings. Genetic polymorphisms of CYP2C19, a key enzyme in the biotransformation of clopidogrel, are known to affect pharmacodynamics and
pharmacokinetics of clopidogrel as low responders often carry low-function CYP2C19 alleles. Other mechanisms of variation include drug interaction with proton pump inhibitors and P2Y12 receptor gene polymorphisms that influence not only the ADP responsiveness but also the extent of platelet inhibition by clopidogrel. Interindividual variability may also reflect the sensitivity and variability of the techniques used to assess platelet activation. The large variations and ranges of ARRIs likely reflected the semiquantitative nature of the data generated by Western Blot analysis.

Similar to previously published human studies, a proportion of cats (2/13) did not respond to clopidogrel. Interestingly, platelets from both nonresponder cats had diminished response to ADP on OA and flow cytometry but maintained normal response to thrombin before and after clopidogrel treatment. Although both flow cytometry and OA identified nonresponders to ADP, they do not examine the same cellular events that occur after ADP stimulation and, therefore, may have different specificities in assessing clopidogrel responsiveness. Nonresponders in this case were more appropriately defined as nonresponders to ADP because no residual platelet activation to ADP was found after clopidogrel treatment. This suggests that cats in this population may have P2Y12 receptor polymorphisms, which will require genetic studies for confirmation. Because clopidogrel resistance is associated with increased morbidity in human patients such as stent thrombosis, recurrent ischemic cardiovascular events and myocardial infarction, further research into the mechanism and clinical significance of clopidogrel resistance in HCM cats is needed.

The present study has several limitations. Firstly, the definition of clopidogrel responsiveness in this study is empiric. Because no information on this subject exists in veterinary medicine, we used guidelines previously established by Gurbel et al., who used a similar concentration of ADP in OA to assess clopidogrel responsiveness in patients undergoing percutaneous coronary intervention. In addition, cut-offs generated in most large-scale clinical trials are highly dependent on the subset of patients studied. It should be noted that the cut-offs used in this study were solely for categorizing the degree of clopidogrel response and should not be used to guide clinical decisions. Future clinical trials examining clopidogrel responses in a large population of HCM or ATE cats are needed. It is unknown at this stage whether the progression of HCM may affect platelet activity in cats. Additionally, the higher concentration of ADP (40 μM) used in OA versus the 20 μM concentrations used for flow cytometry and Western blot is a limitation. Although there is evidence suggesting that acepromazine may decrease platelet aggregation in dogs, its effects on platelet function in cats are poorly understood. Lastly, exclusion of subjects because of sample clotting or inadequate volume of PRP may have led to type I error.

In conclusion, our study shows that platelet activation and aggregation are significantly inhibited by 14 days of clopidogrel treatment. Platelets from cats HO for the A31P mutation were more reactive than control platelets which had a variable response to ADP. Clopidogrel response variability was demonstrated in cats by ADP-Ag, P-selectin expression and VASP phosphorylation suggesting that some cats are pharmacologically resistant to clopidogrel. ADP-Ag and flow cytometry could be useful diagnostic tests in assessing clopidogrel response in cats and should be further investigated to optimize patient outcomes.

**Footnotes**

a Coulter ACT diff, Beckman-Coulter Inc, Miami, FL
b Sigma-Aldrich, St. Louis, MO
c Catalogue: 12-626-80 eBioscience, San Diego, CA
d Catalogue: 13-0411-85, eBioscience, San Diego, CA
e Invitrogen, Carlsbad, CA
f Electron Microscopy Sciences, Hatfield, PA
g Beckman-Coulter FC500 Flow Cytometer, Beckman-Coulter Inc
h BD Biosciences, San Diego, CA
i eBioscience, San Diego, CA
j Polysciences Inc, Warrington, PA
k FlowJo, Tree Str Inc, Ashland, OR
l Calbiochem, La Jolla, CA
m Sigma-Aldrich, St. Louis, MO
n Catalogue Number: Sc-23507, Santa Cruz Biotechnology, INC., Dallas, Texas
o Catalogue Number: Sc-1853, Santa Cruz Biotechnology, INC., Dallas, Texas
p FluroChem E chemiluminescence, ProteinSimple, San Jose, CA
q AlphaView Software, ProteinSimple, San Jose, CA
r Thermo Fisher Scientific, Rockford, IL
s 490-2D Optical Aggregometer, Chrono-Log Corporation, Haverton, PA
t Sigma, St Louis, MO
u Chrono-Log Corporation, Haverton, PA
v Prism 6.0e, GraphPad Software, La Jolla, CA

**Acknowledgment**

This study was funded in part by NIH HL093603 (Harris). The corresponding author is funded by the Morris Animal Foundation (D15CA-907).

**Conflicts of Interest Declaration:** Authors declare no conflict of interest.

**Off-label Antimicrobial Declaration:** Authors declare no off-label use of antimicrobials.

**References**


